InfuSystem's Record Quarter Comes With a $5 Million Invoice
A niche lymphedema growth engine is real, but the ERP stumble and another RCM delay are the parts of the story the tape has not fully priced.
INFU · Earnings Call · 2026-11-10
A record quarter, but not the one the tape expected
InfuSystem is a $292 million market-cap medical-device services company, and its stock has already voted: shares are up 57.7% over the last 90 trading days, a sharp re-rating into the print. That makes the third quarter less about whether the business is growing and more about whether the growth is clean enough to justify the move. The headline is noisy. Reported revenue rose 3% to $37.6 million, but that number is distorted by the GE Healthcare contract restructuring, which deliberately gave back low-margin revenue. On a pro forma basis, revenue grew 10.2% — and that is the real signal. “During the quarter, we achieved record revenue of $37.6 million and after adjusting for the previously announced GE Healthcare contract restructuring, generated pro forma revenue growth of 10.2%.” — Carrie Lachance, Chief Executive Officer · 2026-11-10 The acceleration is visible through the year: pro forma growth moved from 1.7% in Q1 to 7.5% in Q2 to 10.2% in Q3.The pro forma lens is doing real work
This is not financial engineering, but it is a reset. Total revenue reached $37 million, up 3% year over year and 10% sequentially. The quality of that revenue is better: gross margin was 58.0%, up 2.8 percentage points year over year, and adjusted EBITDA margin expanded to 24.9% from 22.8%. The balance sheet also improved, with effective net cash at negative $20 million, a net debt position that has improved by roughly $15 million over the past year. Management ended the quarter with $64.1 million of liquidity and net debt of about $10.6 million, or 0.32x trailing adjusted EBITDA. That is a very different company from the leveraged roll-up of prior cycles.Lymphedema is no longer a call option
The most important operating fact is that Wound Care revenue rose 112% in the quarter, including roughly $1.6 million from compression therapy products. The lymphedema market has moved from a speculative adjacent therapy to a meaningful contributor. The products are compression devices and adjustable compression wraps, and the Q&A made clear this was not channel stuffing. Asked whether the lymphedema strength included stocking or pipeline fill, Carrie Lachance was direct: “No, ongoing new referrals. That's all new business for us.” — Carrie Lachance, Chief Executive Officer · 2026-11-10 That matters because it confirms the growth is demand-led, not a one-time launch fill. It also is not new. On the August call, management was already describing the same engine: “I think we're 154% growth. So we continue to see volume coming in.” — Carrie Lachance, Chief Executive Officer · 2026-08-04 So the market should not treat Q3 as a surprise one-off; it is the fourth or fifth quarter of a compounding niche. The caveat is concentration. Infu depends on a small number of compression partners for referrals and paperwork, and it took reserves on adjustable compression wraps in the quarter. Management says underlying demand remains strong and Q4 volume should look similar to Q3. If that holds, Wound Care can carry the pro forma growth rate while Oncology grinds higher.The ERP invoice stumble is the real tell
The blemish is not demand. It is execution. Barry Steele disclosed roughly $5 million of temporary working capital pressure from billing and invoicing issues after the ERP implementation. “approximately $5 million of temporary working capital pressure during the quarter related to billing and invoicing issues following our ERP implementation.” — Barry Steele, Chief Financial Officer · 2026-11-10 The company says the issue was invoice formatting and customer-specific revisions, not bad debt or reimbursement changes, and that collections improved through September and into October. But this is exactly the kind of self-inflicted wound that matters for a small-cap with a freshly re-rated stock. The prior call had sounded reassuring. In May, Steele said: “We do not think that anything is going to cause any disruptions in our cash flow or billings or anything like that.” — Barry Steele, Chief Financial Officer · 2026-05-07 That did not hold.The receivables ratio tells the same story: receivables to revenue rose to 73.7%, up 5.7 percentage points year over year. The earnings release itself was delayed by 48 hours. Steele said it was “completely resolved” — Barry Steele, Chief Financial Officer · 2026-11-10 and that there were no changes to the financials. The market may accept that. But investors should watch the next two quarters of cash conversion, because the company also pushed the Oncology migration onto the new revenue-cycle system again. In May, management expected Oncology to move by the end of 2026. On this call, Lachance said it might “sneak into Q1 of next year” — Carrie Lachance, Chief Executive Officer · 2026-11-10. That is a pattern of systems projects slipping, even if the underlying business is fine.Importantly, this was not driven by customer demand, reimbursement changes or credit deterioration. The majority of the increase relates to invoices that were either delayed or required customer-specific revisions before payment could be processed.